Melatonin – a go-to sleep aid for kids and adults alike in many households in America – continues to create media buzz, with conflicting messages that leave people uncertain about its safety.
The late-stage pharmaceutical company announces a leadership transition as it prepares for the potential commercialization of its once-daily oral therapy for obstructive sleep apnea.
New research identifies a "strong response endotype" of patients who experience nearly double the sleep apnea improvement from tirzepatide.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.